NASDAQ:ARAYAccuray Stock Price, Forecast & News

Accuray's stock was trading at $2.27 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARAY stock has decreased by 7.5% and is now trading at $2.10. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Accuray.

Accuray is scheduled to release its next quarterly earnings announcement on Thursday, August 20th 2020. View our earnings forecast for Accuray.

Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings data on Tuesday, April, 28th. The medical equipment provider reported $0.03 EPS for the quarter, beating the Zacks' consensus estimate of ($0.04) by $0.07. The medical equipment provider had revenue of $99.55 million for the quarter, compared to analysts' expectations of $96.46 million. Accuray had a net margin of 0.64% and a negative return on equity of 14.83%. View Accuray's earnings history.

2 equities research analysts have issued twelve-month price targets for Accuray's stock. Their forecasts range from $4.00 to $9.50. On average, they expect Accuray's share price to reach $6.75 in the next twelve months. This suggests a possible upside of 221.4% from the stock's current price. View analysts' price targets for Accuray.

Media coverage about ARAY stock has trended very negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Accuray earned a daily sentiment score of -3.4 on InfoTrie's scale. They also gave news articles about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutAccuray.

Accuray saw a increase in short interest in April. As of April 30th, there was short interest totaling 2,960,000 shares, an increase of 41.0% from the April 15th total of 2,100,000 shares. Based on an average daily volume of 667,800 shares, the days-to-cover ratio is currently 4.4 days. Approximately 3.4% of the company's stock are sold short. View Accuray's Current Options Chain.

Some companies that are related to Accuray include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Steris (STE), Hologic (HOLX) and Masimo (MASI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Accuray investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Activision Blizzard (ATVI), Intel (INTC), Tesla (TSLA), Corbus Pharmaceuticals (CRBP), Netflix (NFLX), Abeona Therapeutics (ABEO), Amarin (AMRN) and AVEO Pharmaceuticals (AVEO).

Accuray trades on the NASDAQ under the ticker symbol "ARAY."

Accuray's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.07%), Primecap Management Co. CA (4.79%), Russell Investments Group Ltd. (3.93%), JPMorgan Chase & Co. (2.26%), State Street Corp (1.85%) and Geode Capital Management LLC (1.47%). Company insiders that own Accuray stock include Alaleh Nouri, Andrew J Kirkpatrick, Jesse Chew, Joseph E Whitters, Joshua Levine, Kevin Waters, Patrick Spine and Shigeyuki Hamamatsu. View institutional ownership trends for Accuray.

ARAY stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Investments LP, Primecap Management Co. CA, UBS Group AG, Squarepoint Ops LLC, Morgan Stanley, Spark Investment Management LLC, and Assenagon Asset Management S.A.. Company insiders that have sold Accuray company stock in the last year include Andrew J Kirkpatrick, Jesse Chew, Joshua Levine, and Shigeyuki Hamamatsu. View insider buying and selling activity for Accuray.

ARAY stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Voce Capital Management LLC, Wellington Management Group LLP, Cowen Prime Services LLC, GSA Capital Partners LLP, Russell Investments Group Ltd., Dupont Capital Management Corp, and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have bought Accuray stock in the last two years include Joseph E Whitters, and Joshua Levine. View insider buying and selling activity for Accuray.

Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ARAY stock can currently be purchased for approximately $2.10.

Accuray has a market capitalization of $190.09 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.

The official website for Accuray is www.accuray.com.

Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]